Focus: Peptilogics is a public biotech company headquartered in Pittsburgh, PA, specializing in peptide therapeutics for neurology and infectious disease. The company is in early-stage clinical development with a focused pipeline targeting unmet medical needs.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
Peptilogics is a high-risk, early-stage opportunity best suited for scientifically ambitious biotech veterans willing to bet on an unproven peptide platform; not recommended for those seeking stability or clear advancement paths.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Peptilogics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Peptilogics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
University of Cincinnati launches clinical trial to test new drug for prosthetic joint infections - News-Medical
University of Cincinnati launches clinical trial to test new drug for prosthetic joint infections News-Medical
Peptilogics begins trial of drug designed to cure medical device-related infections - Medical Economics
Peptilogics begins trial of drug designed to cure medical device-related infections Medical Economics
Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections - Business Wire
Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections Business Wire
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Peptide Therapeutics in Orthopaedics: Current Evidence and Future Directions.
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of a First-in-Human Engineered Cationic Peptide, PLG0206, Intravenously Administered in Healthy Subjects.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo